Lomustine is an alkylating drug indicated for the treatment of patients with brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures, among other approved uses. It is available as capsules for oral use. MedsAcross supplies Lomustine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Lomustine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy.
Source: US FDA prescribing information
Lomustine alkylates DNA and RNA. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Source: US FDA prescribing information
Recommended dose in adult and pediatric patients is 130 mg/m 2 orally every 6 weeks. Round dose to nearest 10 mg. Give as a single oral dose and do not repeat for at least 6 weeks.
Source: US FDA prescribing information
None.
Source: US FDA prescribing information
Boxed warning (delayed myelosuppression and risk of overdosage delayed myelosuppression): Lomustine causes myelosuppression including fatal myelosuppression. Myelosuppression is delayed, dose-related, and cumulative, occurring 4 to 6 weeks after drug administration and persisting for 1 to 2 weeks. Thrombocytopenia is generally more severe than leukopenia. Pulmonary toxicity: Pulmonary infiltrates and/or fibrosis occurs with lomustine. Perform pulmonary function tests prior to treatment and repeat frequently. Permanently discontinue lomustine in patients diagnosed with pulmonary fibrosis. Secondary malignancies: Acute leukemia and myelodysplasia can occur with long-term use. Hepatotoxicity: Increased levels of transaminases, alkaline phosphatase and bilirubin can occur with lomustine. Monitor liver function. Nephrotoxicity: Can cause renal failure. Monitor renal function.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Delayed myelosuppression Risks of overdosage Pulmonary toxicity Secondary malignancies Hepatotoxicity Nephrotoxicity The following adverse reactions associated with the use of lomustine were identified in clinical trials or postmarketing reports. Because these reactions were reported from a population of uncertain size, it is not possible to estimate their frequency, reliability, or establish a causal relationship to drug exposure. Gastrointestinal disorders: nausea, vomiting, and stomatitis Ocular disorders: optic atrophy, visual disturbances, and blindness Neurologic disorders: disorientation, lethargy, ataxia, and dysarthria Other: alopecia Common adverse reactions include delayed myelosupression, nausea, vomiting, stomatitis, and alopecia.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Avoid temperatures over 40°C (104°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Lomustine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Gleostine 10 mg capsuleOral | Azurity Pharmaceuticals | US FDA | Available on request |
| Gleostine 100 mg capsuleOral | Azurity Pharmaceuticals | US FDA | Available on request |
| Gleostine 40 mg capsuleOral | Azurity Pharmaceuticals | US FDA | Available on request |
| Lomustine 10 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Lomustine 100 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Lomustine 40 mg capsuleOralGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 4 August 1976 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Lomustine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 6 presentations of Lomustine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Lomustine, including Gleostine.
Yes. The US FDA first approved Lomustine on 4 August 1976, according to Drugs@FDA.
No listed presentation of Lomustine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lomustine is classified under ATC code L01AD02 (Lomustine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.